Business
NEUPATH HEALTH THE FIRST NORTH AMERICAN PROVIDER OF ARTHROSAMID®, A REVOLUTIONARY INJECTION FOR KNEE OSTEOARTHRITIS
Arthrosamid can provide pain relief for knee osteoarthritis patients for up to four years after a...
About this update from Neupath Health Inc.
[{"type":"text","content":"NEUPATH HEALTH THE FIRST NORTH AMERICAN PROVIDER OF ARTHROSAMID®, A REVOLUTIONARY INJECTION FOR KNEE OSTEOARTHRITIS\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignt { vertical-align: top }\n \n\n\n\n\n Arthrosamid can provide pain relief for knee osteoarthritis patients for up to four years after a single procedure\n \n\n NeuPath continues to accelerate growth as it rolls out Arthrosamid across its clinic network\n \n\n Empowers NeuPath healthcare physicians to deliver innovative, best-in-class treatment to Canadians\n \n\n\n\n\n NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that it has performed the first-ever injection of Arthrosamid in North America at its Mississauga, Ontario clinic. Prior to Health Canada’s approval of Arthrosamid, patients would travel to Europe to access this innovative hydrogel that has been shown to provide up to four years of pain relief for knee osteoarthritis sufferers.\n \n 1\n \n\n\n “This is a major step forward in osteoarthritis options for Canadians,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “It underscores our commitment to provide best chronic pain care to our patients as we scale up our clinic network and expand our services across Canada. We continue to seek out proven, innovative treatments that leverage our growing market presence and the skills of our healthcare professionals.”\n \n\n Over four million Canadians live with osteoarthritis, with knee osteoarthritis being a leading cause of pain, mobility issues and reduced quality of life. The economic burden of arthritis\n \n\n in Canada was estimated to be $6.4 billion, representing almost one third of the total cost of musculoskeletal diseases.\n \n 2\n \n Worldwide, osteoarthritis is a leading cause of disability in older adults.\n \n 3\n \n Conventional non-surgical solutions like painkillers and corticosteroid injections provide only temporary relief. The addition of Ar...